NUTEX HEALTH INC (NUTX) Stock Fundamental Analysis
NASDAQ:NUTX - Nasdaq - US67079U3068 - Common Stock - Currency: USD
NUTX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 103 industry peers in the Health Care Providers & Services industry. NUTX has only an average score on both its financial health and profitability. NUTX is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make NUTX suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
In the past year NUTX was profitable.
NUTX had a positive operating cash flow in the past year.
In the past 5 years NUTX reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NUTX reported negative operating cash flow in multiple years.
1.2 Ratios
NUTX has a better Return On Assets (8.82%) than 92.23% of its industry peers.
NUTX has a better Return On Equity (34.08%) than 96.12% of its industry peers.
With an excellent Return On Invested Capital value of 30.54%, NUTX belongs to the best of the industry, outperforming 99.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROIC | 30.54% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NUTX's Profit Margin of 10.76% is amongst the best of the industry. NUTX outperforms 96.12% of its industry peers.
The Operating Margin of NUTX (33.39%) is better than 99.03% of its industry peers.
The Gross Margin of NUTX (48.77%) is better than 74.76% of its industry peers.
NUTX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NUTX is creating value.
The number of shares outstanding for NUTX has been reduced compared to 1 year ago.
Compared to 5 years ago, NUTX has more shares outstanding
Compared to 1 year ago, NUTX has an improved debt to assets ratio.
2.2 Solvency
NUTX has an Altman-Z score of 2.17. This is not the best score and indicates that NUTX is in the grey zone with still only limited risk for bankruptcy at the moment.
NUTX has a Altman-Z score (2.17) which is in line with its industry peers.
NUTX has a debt to FCF ratio of 4.45. This is a neutral value as NUTX would need 4.45 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.45, NUTX is in the better half of the industry, outperforming 69.90% of the companies in the same industry.
NUTX has a Debt/Equity ratio of 1.46. This is a high value indicating a heavy dependency on external financing.
NUTX has a worse Debt to Equity ratio (1.46) than 69.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Altman-Z | 2.17 |
ROIC/WACC4.2
WACC7.27%
2.3 Liquidity
A Current Ratio of 2.27 indicates that NUTX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.27, NUTX is in the better half of the industry, outperforming 78.64% of the companies in the same industry.
NUTX has a Quick Ratio of 2.26. This indicates that NUTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.26, NUTX is in the better half of the industry, outperforming 79.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
NUTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 430.28%, which is quite impressive.
NUTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 141.25%.
The Revenue has been growing by 222.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
3.2 Future
Based on estimates for the next years, NUTX will show a decrease in Earnings Per Share. The EPS will decrease by -3.20% on average per year.
Based on estimates for the next years, NUTX will show a very strong growth in Revenue. The Revenue will grow by 64.29% on average per year.
EPS Next Y23.85%
EPS Next 2Y-3.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year157.09%
Revenue Next 2Y64.29%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.34, the valuation of NUTX can be described as reasonable.
Based on the Price/Earnings ratio, NUTX is valued cheaply inside the industry as 91.26% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.92, NUTX is valued rather cheaply.
The Price/Forward Earnings ratio is 15.02, which indicates a correct valuation of NUTX.
NUTX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NUTX is cheaper than 75.73% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of NUTX to the average of the S&P500 Index (21.49), we can say NUTX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.34 | ||
| Fwd PE | 15.02 |
4.2 Price Multiples
97.09% of the companies in the same industry are more expensive than NUTX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, NUTX is valued cheaply inside the industry as 86.41% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.86 | ||
| EV/EBITDA | 3.95 |
4.3 Compensation for Growth
NUTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of NUTX may justify a higher PE ratio.
A cheap valuation may be justified as NUTX's earnings are expected to decrease with -3.20% in the coming years.
PEG (NY)0.43
PEG (5Y)N/A
EPS Next 2Y-3.2%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NUTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
122.9
+4.44 (+3.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners18.53%
Inst Owner Change-80.67%
Ins Owners3.16%
Ins Owner Change0%
Market Cap684.55M
Analysts82.22
Price Target197.54 (60.73%)
Short Float %6.37%
Short Ratio1.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.25
Dividend Growth(5Y)N/A
DP19.83%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4474.63%
Min EPS beat(2)9.6%
Max EPS beat(2)8939.67%
EPS beat(4)3
Avg EPS beat(4)2105.75%
Min EPS beat(4)-602.61%
Max EPS beat(4)8939.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)143.87%
Min Revenue beat(2)76.42%
Max Revenue beat(2)211.33%
Revenue beat(4)4
Avg Revenue beat(4)75.65%
Min Revenue beat(4)5.5%
Max Revenue beat(4)211.33%
Revenue beat(8)5
Avg Revenue beat(8)36.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)89.87%
PT rev (3m)204.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)505.3%
EPS NY rev (1m)95.39%
EPS NY rev (3m)752.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)120.71%
Revenue NY rev (1m)67.95%
Revenue NY rev (3m)124.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.34 | ||
| Fwd PE | 15.02 | ||
| P/S | 1.1 | ||
| P/FCF | 9.86 | ||
| P/OCF | 9.63 | ||
| P/B | 3.47 | ||
| P/tB | 4.08 | ||
| EV/EBITDA | 3.95 |
EPS(TTM)11.89
EY9.67%
EPS(NY)8.18
Fwd EY6.66%
FCF(TTM)12.47
FCFY10.14%
OCF(TTM)12.76
OCFY10.38%
SpS112.08
BVpS35.39
TBVpS30.16
PEG (NY)0.43
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROCE | 35.61% | ||
| ROIC | 30.54% | ||
| ROICexc | 35.64% | ||
| ROICexgc | 37.81% | ||
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% | ||
| FCFM | 11.12% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
F-Score8
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Debt/EBITDA | 1.26 | ||
| Cap/Depr | 8.22% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 59.03 | ||
| Cash Conversion | 31.12% | ||
| Profit Quality | 103.36% | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 2.17 |
F-Score8
WACC7.27%
ROIC/WACC4.2
Cap/Depr(3y)59.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
EPS Next Y23.85%
EPS Next 2Y-3.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
Revenue Next Year157.09%
Revenue Next 2Y64.29%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4652.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1064.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y98.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.51%
OCF growth 3YN/A
OCF growth 5YN/A